We take a full-circle approach to product development, from the grassroots level to the lab to legislative bodies.


To translate scientific discoveries into affordable, globally accessible public health solutions.


A world where all people have equitable access to innovative vaccines and therapeutics.

Our health areas

  • HIV
  • Tuberculosis
  • Lassa fever
  • Marburg virus
  • Sudan Ebolavirus
  • COVID-19


The challenge

HIV/AIDS remains one of the deadliest infectious diseases, with 1.3 million people acquiring HIV in 2022. Given the complexities of HIV, traditional approaches to vaccine development have so far failed to result in a vaccine that provides protection against HIV. However, a vaccine is still needed to bring a true end to the HIV pandemic. Source: UNAIDS

Our solution

IAVI scientists and our collaborators are developing next-generation HIV vaccines to address the challenges of HIV vaccine design. Together, we have pioneered promising new vaccination strategies and the discovery of broadly neutralizing antibodies (bnAbs) against HIV. IAVI and our partners are developing HIV bnAbs to prevent HIV acquisition while we advance vaccine candidates.


The challenge

Tuberculosis (TB) is the world’s leading infectious disease killer. In 2022, 10.6 million people fell ill with TB and 1.3 million people died of TB disease. The only available TB vaccine is the century-old Bacille Calmette-Guérin, or BCG. While this vaccine has efficacy in protecting against severe TB disease in infants and young children, it is largely ineffective in adolescents and adults, among whom most transmission and disease occurs. Source: WHO

Our solution

IAVI works across our global hubs with a diverse network of partners to advance the most promising TB vaccine candidates from discovery through clinical trials, and eventually, to post-licensure access. Our work extends to policy and advocacy initiatives that support TB vaccine development and access in regions where new vaccines are needed most.

Lassa fever

The challenge

Lassa fever is an acute viral hemorrhagic illness endemic to West Africa that causes significant annual outbreaks of disease. Lassa fever is difficult to diagnose, and surveillance data is limited. Current estimates range from 300,000 to 500,000 cases and 5,000 related deaths each year. No licensed vaccines for Lassa fever exist. Source: WHO

Our solution

IAVI is developing a single-dose vaccine candidate for Lassa that is based on a recombinant vesicular stomatitis virus (rVSV) vector. This technology is similar to that underlying an approved Ebola Zaire virus vaccine. IAVI’s Lassa vaccine candidate was well tolerated and immunogenic over a wide dose range in a Phase I clinical study. IAVI also conducts Lassa epidemiological studies and modeling to support future vaccine access.

Marburg virus

The challenge

Marburg virus is a filovirus and the causative agent of Marburg virus disease (MVD), which has a case fatality ratio of up to 88%. Marburg virus has the capacity to cause outbreaks with high fatality rates and is a potential bioterror threat. No vaccines or antiviral treatments are approved for MVD. A Marburg vaccine is urgently needed to respond to future outbreaks. Source: WHO

Our solution

IAVI is developing a vaccine candidate for Marburg that is based on a recombinant vesicular stomatitis virus (rVSV) vector. This technology is similar to that underlying an approved Ebola Zaire virus vaccine, which is now approved by the U.S. FDA and registered for use in several African countries. Preclinical data demonstrates that IAVI’s Marburg vaccine candidate is highly protective in an animal model with one dose.

Sudan Ebolavirus

The challenge

Sudan ebolavirus is a filovirus and causes outbreaks of Ebola disease, most recently in 2022 in Uganda. Case fatality rates of Ebola disease caused by Sudan ebolavirus have varied from 41% to 100% in past outbreaks. The licensed vaccine for Ebola Zaire virus does not provide cross protection against the Sudan strain. An Ebola Sudan vaccine is urgently needed to prevent and respond to future outbreaks. Source: WHO

Our solution

IAVI is developing a vaccine candidate for Sudan ebolavirus that is based on a recombinant vesicular stomatitis virus (rVSV) vector similar to the technology underlying an approved Ebola Zaire virus vaccine. During the 2022 Ebola outbreak in Uganda, the WHO selected IAVI’s Sudan ebolavirus vaccine candidate for a planned ring vaccination trial. While the trial did not go forward due to outbreak control, IAVI has continued clinical development to prepare for future outbreaks.


The challenge

Since December 2019, over 760 million cases of COVID-19 and 6.9 million deaths have been recorded worldwide, but the actual number is thought to be higher. While highly effective, approved COVID-19 vaccines do not fully block transmission or breakthrough infection. Additional COVID-19 vaccines continue to be an urgent need, particularly vaccines suitable for widespread use in middle and low-income countries. Source: WHO

Our solution

IAVI is developing a COVID-19 vaccine candidate that is based on a recombinant vesicular stomatitis virus (rVSV) vector. The vaccine candidate has demonstrated safety in humans when administered intramuscularly and has been produced at scale to support larger future clinical trials. IAVI is also investigating an intranasal formulation of our COVID-19 vaccine candidate to prevent infection.

Our impact

We conduct preclinical and clinical trials of our own vaccines and antibodies. Our focus is on diseases of global importance for which there is no market and little financial incentive for development. We also collaborate with and support other scientific organizations to conduct their own clinical trials of priority disease prevention and therapeutic interventions.

255 partners from academic, biotech, pharma sectors, civil society, and global health initiatives

53 biologics candidates supported by the IAVI Product Development Center, out of which 25 advanced to clinical trials

70,000 volunteers enrolled in observational epidemiology studies

Our locations

IAVI Africa

  • Cape Town Office, South Africa
  • Nairobi Office, Kenya

IAVI Europe

  • Amsterdam Office, The Netherlands
  • Human Immunology Lab, London, U.K.

IAVI India

  • Gurugram, Haryana Office
  • Antibody Translational Research Program, IAVI-THSTI, Faridabad


  • New York Office
  • Vaccine Design & Development Lab, New York
  • Neutralizing Antibody Center, California

Recent news & media


Research from the IAVI Neutralizing Antibody Center and partners provides additional evidence for germline-targeting strategy of HIV vaccine development

New research published May 30 in two papers in Nature Immunology demonstrates that vaccination can induce broadly neutralizing antibody (bnAb) precursors to HIV glycoprotein 41 (gp41), an important potential vaccination target, in mice and non-human primates. Results from both studies, which focus on membrane-proximal external region (MPER) antibodies, provide additional evidence supporting and guiding the […]
Read More
Body bent towards the skin surface, this image depicts a lateral view of a feeding female Anopheles merus mosquito. This specimen had landed on a human hand, and was in the process of obtaining its blood meal through its sharp, needle-like labrum, which it had inserted into its human host. Note the reddish color of the labrum, as it was filled with blood, and the retracted labium, which ensheaths the sharp labrum when it’s not in use. Also note the red-colored abdomen that had become enlarged due to its blood meal contents. A member of the A. gambiae species complex, A. merus is a known vector for the parasitic disease malaria.
IAVI Report

Will monoclonal antibodies be a new weapon in the fight against malaria?

Monoclonal antibodies have revolutionized the treatment of cancer, autoimmune diseases, and inflammation in wealthier countries. But their role in treating and preventing infectious diseases was limited. Until COVID-19. The emergence of SARS-CoV-2 heralded the first time that mAbs were mass produced — millions of doses were manufactured and administered in the U.S. alone — to […]
Read More

IAVI recognizes HIV Vaccine Awareness Day as new papers are published

Every year on May 18, the global HIV community observes HIV Vaccine Awareness Day, a day to recognize the long quest to produce one of the holy grails of public health tools: an effective vaccine that could bring an end to HIV. There are many reasons why an HIV vaccine remains necessary, even in a […]
Read More
Scientists working at the IAVI Human Immunology Laboratory in London

IAVI’s Human Immunology Laboratory relocates samples to Africa, fulfilling capacity strengthening goal

IAVI is proud to announce that after more than 20 years of strengthening scientific capacity in partner African and Indian laboratories to enable sustainable independent research and diagnostics activities in those regions, it has relocated key assets from the biorepository of samples stored at the IAVI U.K.-based Human Immunology Laboratory (HIL) to the Aurum Institute […]
Read More
Frontiers Tb Feature

TB vaccine workshop report published in Frontiers in Tuberculosis

In October 2023, the Stop TB Partnership Working Group on New Vaccines (WGNV), IAVI, and the London School of Hygiene & Tropical Medicine co-hosted a workshop with tuberculosis (TB) high-burden country experts to build understanding of what epidemiological, impact, feasibility, and acceptability data would be needed to plan for TB vaccine introduction at the national […]
Read More
Antibodies in the blood
IAVI Report

Rethinking antibodies for infectious diseases?

The COVID-19 pandemic was the first time monoclonal antibody-based therapies were produced in mass quantities to combat an infectious disease. Clinics administered hundreds of thousands of antibody infusions and injections over the first two years of the pandemic with the aim of staving off the worst outcomes of SARS-CoV-2 infection. It worked — at least […]
Read More